Multiplex ligation-dependent probe amplification (MLPA) enhances the molecular diagnosis of aniridia and related disorders by Redeker, Egbert J.W. et al.
Multiplex ligation-dependent probe amplification (MLPA)
enhances the molecular diagnosis of aniridia and related disorders
Egbert J.W. Redeker,1 Annette S.H. de Visser,1 Arthur A.B. Bergen,1,2 Marcel M.A.M. Mannens1
1Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The
Netherlands; 2Department of Clinical and Molecular Ophthalmogenetics, The Netherlands Institute for Neuroscience, an institute
of the Royal Netherlands Academy of Arts and Sciences (KNAW), Amsterdam, The Netherlands
Mutations in the PAX6 gene have been implicated in aniridia, a congenital malformation of the eye with severe hypoplasia
of the iris. However, not all aniridia cases can be explained by mutations in the PAX6 gene. The purpose of this study was
to enhance the molecular diagnosis of aniridia using multiplex ligation-dependent probe amplification (MLPA). Total
genomic DNA was isolated from peripheral blood of 70 unrelated probands affected with aniridia. Polymerase chain
reaction (PCR) was performed followed by automated bidirectional sequencing. Additionally, MLPA was performed. We
identified 24 different point mutations in the PAX6 gene in 34 patients after sequencing. In eight additional patients, we
identified a deletion of one or more exons of the PAX6 gene or in the 3′ regulatory region of the PAX6 gene using MLPA.
This work demonstrates the necessity to screen for larger deletions in the region of the PAX6 gene in addition to the
sequencing of exons in the PAX6 gene. The mutation detection rate will increase from 49% to 60%. This shows that MLPA
substantially enhances the molecular diagnosis of aniridia.
Aniridia (AN2; OMIM 106210) is a genetic disorder,
which is characterized by iris hypoplasia as well as several
other  ocular  features  such  as  cataract,  glaucoma,  corneal
opacity, and nystagmus. The aniridia gene was mapped to
chromosome 11p13, and no other locus besides chromosome
11p13  was  convincingly  implicated  in  aniridia  [1].
Heterozygous mutations in the paired box gene 6 (PAX6;
OMIM 607108), located on human chromosome 11p13, were
previously implicated in familial and sporadic aniridia. The
functional relationship between the gene and the disease was
further enhanced by the finding that PAX6 mutations cause
the small eye (sey) phenotype in mice [2]. PAX6 is clearly the
major if not only gene responsible for the disease. A frequently
updated summary of PAX6 mutations, which are associated
with aniridia and related disorders, is documented at the PAX6
allelic variation database [3]. PAX6 is highly conserved, and
missense mutations can also cause dysfunction of the protein
[4]. In isolated aniridia cases, published PAX6 alterations
comprise mainly point mutations [1]. The majority of these
mutations  result  in  premature  termination  of  the  PAX6
protein. A proportion of aniridia cases are associated with the
WAGR (Wilms tumor, aniridia, genitourinary abnormalities,
mental retardation) syndrome. WAGR is a contiguous gene
syndrome  arising  from  deletions  of  chromosome  11p13,
which encompass at least both the PAX6 and WT1 genes. In
contrast, only a few isolated aniridia patients with a gross
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deletion or a cytogenetic translocation in the PAX6 region
have been reported in the literature [5-10]. Gross deletions
may be underreported due to the fact that these are not always
detected by FISH (fluorescent in situ hybridization) and that
these are not detected by the common mutation detection
methods such as SSCP, DHPLC, or sequencing.
We  performed  a  mutation  analysis  for  PAX6  in  70
unrelated patients with aniridia. By scanning the 14 exons of
PAX6,  24  different  point  mutations  were  identified  in  34
patients. In addition, we detected gross deletions in another
eight  patients  using  multiplex  ligation-dependent  probe
amplification (MLPA).
METHODS
Patients: The patient group consisted of 70 patients who were
referred  to  our  laboratory  with  the  clinical  diagnosis  of
isolated aniridia. The study was performed according to a
protocol approved by the local ethics committee.
DNA analysis: Genomic DNA was isolated from peripheral
blood. All 14 exons of the PAX6 gene were amplified and
sequenced bidirectionally on an ABI PRISM 377 sequencer
(Applied  Biosystems,  Foster  City,  CA)  using  standard
technology and the primers described in Table 1. The mutation
nomenclature is according to the recommendations of the
Human Genome Variation Society [11]. cDNA nucleotide
numbering  (reference  sequence  NM_001604.3  from
GenBank) starts with +1 at the A of the ATG translation
initiation codon. Probes for MLPA analysis (SALSA MLPA
Kits P097 and P219) were purchased from MRC Holland
(Amsterdam,  the  Netherlands).  MLPA  was  performed
according to the manufacturer’s instructions. In summary, 100
Molecular Vision 2008; 14:836-840 <http://www.molvis.org/molvis/v14/a99>
Received 25 October 2007 | Accepted 11 April 2008 | Published 7 May 2008
© 2008 Molecular Vision
836ng DNA was denatured and hybridized overnight at 60 °C with
SALSA probe mix. After treating the samples with ligase 65
for  15  min  at  54  °C,  polymerase  chain  reaction  (PCR)
amplification was performed with the specific SALSA FAM
PCR  primers.  Electrophoresis  of  PCR  products  was
performed using an ABI PRISM 310 (Applied Biosystems).
Data analysis was performed by exporting the peak areas to a
Microsoft  Excel  file.  Sample-related  and  peak-related
differences  in  PCR  and  electrophoresis  efficiency  were
corrected by first calculating the peak area relative to the sum
of peak areas per sample and subsequently expressing each
normalized peak area relative to the mean of that peak across
samples. To detect deviating peaks, each normalized peak was
divided by the mean of that peak in the control samples. Peak
areas outside the range 0.7–1.3 times the control peak area
were considered abnormal with those below 0.7 representing
deletions and those above 1.3 representing duplications. All
normal samples run in one assay showed standard deviations
Figure  1.  Detection  of  PAX6  exon  9  deletion  by  MLPA.
Electropherograms are from a normal control and from the patient
with an exon 9 deletion. The deletion is apparent by a ~50% reduction
in peak area of the PAX6 exon 9 specific probe (red arrow).
of less than 10% of the mean. Several control samples were
included  in  each  MLPA  experiment.  Each  result  was
confirmed by two independent tests.
Long range polymerase chain reaction: For confirmation of
the  PAX6  exon  9  deletion,  PCR  was  performed  with  the
following primer combination: 5′-GGA CTT CGG TGC CAG
GGC AAC CTA-3′ (forward) located in exon 8 and 5′-TGG
CTG CTA GTC TTT CTC GGG CAA ACA-3′ (reverse)
located in exon 10.
Fluorescent  in  situ  hybridazation:  FISH  analysis  was
performed  according  a  standard  protocol  using  the  FISH
probes, FAT5 (PAX6), p60 (D11S324), and B2.1 (WT1) as
described by Crolla et al. [7].
RESULTS
We performed a mutation analysis for PAX6 in 70 unrelated
patients with isolated aniridia. By scanning the 14 exons of the
PAX6 gene, 24 different point mutations were identified in 34
patients  (Table  2).  We  identified  the  following  types  of
mutations: a frameshift mutation in nine patients; a splice-site
mutation in seven patients; a nonsense mutation in 11 patients;
in three patients a no-stop change; and in four patients a
missense mutation.
It is known that PAX6 missense mutations may give rise
to variant phenotypes [4]. Of the four patients with missense
mutations  in  our  study,  three  have  phenotypes  within  the
classical aniridia spectrum. The fourth case, patient 44 with
the p.Arg26Pro mutation, is a familial aniridia case with an
affected mother and daughter. The daughter has ectopic pupils
and marked atrophy of the iris stroma as well as congenital
nystagmus  and  cataract.  The  mother  has  nystagmus,
microcornea,  coloboma  of  the  iris  with  iridocorneal
adhesions, some stromal atrophy, and peripheral coloboma of
the choroid of one eye.
TABLE 1. LIST OF PRIMERS USED TO PERFORM AMPLIFICATION AND SEQUENCING OF THE 14 PAX6 EXONS.
Exon Forward primer Reverse primer
1 AGGGAACCGTGGCTCGGC GGGTGAGGGAAGTGGCTGC
2 TTATCTCTCACTCTCCAGCC GGAGACCTGTCTGAATATTGC
3 TCAGAGAGCCCATCGACGTAT CTGTTTGTGGGTTTTGAGCC
4 AGTTCAGGCCTACCTGATGC GTCGCGAGTCCCTGTGTC
5 CTCCCTCATCTTCCTCTTCC GGGGTCCATAATTAGCATCG
6–7 GGGCTACAAATGTAATTTTAAGAAA AGAGAGGGTGGGAGGAGGTA
8 GAGCTGAGATGGGTGACTG GAGAGTAGGGGACAGGCAAA
9 AGACTACACCAGGCCCCTTT TGAAGATGTGGCATTTACTTTGA
10 GGAACCAGTTTGATGCACAG ACTCTGTACAAGCACCTCTGTCTC
11 GGGCTCGACGTAGACACAGT GGAAACTGAGGGCAAGAGAA
12 CGGGCTCTGACTCTCACTCT GCCACTCCTCACTTCTCTGG
13 GCTGTGGCTGTGTGATGTGT AGGAGATTCTGTTTGGGTA
14 TCCATGTCTGTTTCTCAAAGG TCAACTGTTGTGTCCCCATAG
Sequences of primers used to perform amplification and sequencing of the 14 PAX6 exons.
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837We  examined  the  remaining  36  patients  in  which  no
mutation  was  yet  identified  by  means  of  the  multiplex
ligation-dependent probe amplification (MLPA) method. An
example MLPA result is shown in Figure 1. Using the P219
MLPA kit, a deletion was detected in eight isolated aniridia
patients  (Table  3).  In  six  cases,  a  deletion  of  several
contiguous exons was found; in one case, a deletion of a single
exon was found; and in another case, a deletion outside the
coding region of PAX6 was identified. These first six deletions
were confirmed with the MLPA P097 kit. This MLPA kit is
an early version of the PAX6 kit with probes for a limited
number of PAX6 exons. The deletion of exon 9 was confirmed
by long range PCR. The last deletion is a deletion of three
contiguous probes of ELP4 and DCDC1 (Figure 2).
For validation of the MLPA method, we also analyzed
the DNA of two WAGR patients with deletions that were
previously detected by FISH (Table 3). One WAGR patient
TABLE 2. POINT MUTATIONS IN THE PAX6 GENE.
Patient DNA change Consequence Reference
1 and 53 c.-52+1G>A Splice defect [15]
6 and 74 c.301delG p.Glu101LysfsX22 Database*
9 c.489T>G p.Tyr163X New
11, 12 c.399+5G>A Splice defect New
16 c.181_189delinsCA p.Tyr61GlnfsX15 New
19 c.34G>C p.Gly12Arg New
20 c.406C>T p.Gln136X [16]
21 c.-52+5G>C Splice defect New
22, 48, 75 c.1268A>T p.X423Leu [17]
23, 29, 79 c.718C>T p.Arg240X [18]
26 c.640A>G p.Arg214Gly New
30, 49 c.114_121del8 p.Pro39HisfsX13 New
35 c.844_845delCC p.Pro282X New
36 c.112delC p.Arg38GlyfsX15 New
37 c.117insGGCC p.Cys40GlyfsX15 New
41, 51, 68 c.949C>T p.Arg317X [16]
42 c.299G>A p.Trp100X [19]
44 c.77G>C p.Arg26Pro New
58 c.365C>A p.Ser122X New
61 c.400–1G>C Splice defect New
63 c.143T>A p.Val48Glu New
64 c.1074+1G>A Splice defect [15]
66 c.265_266insC p.Gln89ProfsX2 New
76 c.781C>T p.Arg261X [15]
The  asterisk  indicates  the  Human  PAX6  Allelic  Variant
Database.
showed a deletion of all 11p13 probes while the other WAGR
patient  had  a  deletion  of  DCDC1  exon  1  up  to  HIPK3
including PAX6 and WT1.
DISCUSSION
In this study, we showed that by using MLPA, it is possible
to  extend  the  number  of  confirmed  aniridia  cases  at  the
molecular level. In our series of 70 isolated aniridia cases, we
detected PAX6 pathogenic sequence changes in 42 patients;
34 of whom had single nucleotide mutations (49%) and eight
had deletions detected by MLPA (11%). In three of these eight
cases, we found a deletion of all PAX6 exons including the
surrounding genes. In four of the eight cases, there is a partial
deletion of PAX6. In one case, a deletion of ELP4 and DCDC1
was found, leaving PAX6 itself intact. ELP4 and DCDC1 are
located downstream of PAX6. Deletions in this region were
described previously in aniridia patients [10,12]. This region
contains 3′ regulatory elements for PAX6 [13,14].
In spite of the multiplicity and high sensitivity of methods
used, we could not give a molecular diagnosis to 40% of the
patients  investigated.  This  may  be  partly  the  result  of
misdiagnosis; in other cases, it might be the result of the
methods used. Point mutations or deletions might occur in
regions of PAX6 that are not currently investigated such as
intronic or remote promoter regions or in the 3′ regulatory
region.  Balanced  rearrangements  are  not  excluded  either.
There is no evidence to suspect that other genes besides PAX6
are responsible for aniridia [1].
Until now, most large deletions in or near PAX6 have
been identified by FISH or Southern blot analysis. However,
these techniques lack the resolution of MLPA in detecting
smaller deletions or are not generally applicable to detect all
kind of deletions. For our MLPA analysis, we used the P219
MLPA kit, which is an improved version of the P097 kit. Six
of the eight deletions are detected by both kits. The P097 kit
failed to detect two deletions as this kit lacks the relevant
probes.
TABLE 3. GROSS DELETIONS IDENTIFIED BY MLPA KIT P219 IN EIGHT ISOLATED ANIRIDIA PATIENTS AND IN TWO WAGR PATIENTS AS WELL AS THE RESULTS OF THE FISH
ANALYSIS ON THESE PATIENTS.
Patient Deleted PAX6 exons Other deleted probes* Confirmation Deleted FISH probes
4 exon 8–14 - MLPA kit P097 -
5 exon 8–14 - MLPA kit P097 -
17 exon 9 - Long range PCR -
45 exon 9–14 - MLPA kit P097 -
50 exon 1–14 DCDC1 exon 4 - LOC646008 exon 4 MLPA kit P097 ND**
57 exon 1–14 ELP4 - DKFZ exon 3 MLPA kit P097 ND**
69 exon 1–14 DCDC1 exon 4- DKFZ exon 1 MLPA kit P097 -
71 - DCDC1 exon 4 - ELP4 contiguous probes -
WAGR1 exon 1–14 DCDC1 exon 4 – HIPK3 MLPA kit P097 FAT5, p60, B2.1
WAGR2 exon 1–14 BDNF exon 2 - CD44 MLPA kit P097 FAT5, p60, B2.1
The asterisk indicates that the first and the last deleted probes are mentioned. The double asterisk indicates that no lymphocytes
were available for FISH analysis.
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838Young individuals with aniridia but no family history of
aniridia are usually tested by high resolution cytogenetic or
FISH  analysis.  This  is  done  to  detect  a  contiguous  gene
deletion  involving  11p13  and  consequently  to  identify
individuals with an increased risk for Wilms tumor. It is now
also possible to detect this type of deletion by using MLPA,
which has the advantage of a higher resolution than FISH
analysis and strongly reduces the time and cost of analysis.
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